IMPA2
Basic information
Region (hg38): 18:11981025-12030877
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
- not_specified (41 variants)
- not_provided (3 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the IMPA2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000014214.3. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 0 | |||||
| missense | 39 | 42 | ||||
| nonsense | 0 | |||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 0 | 0 | 39 | 2 | 1 |
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| IMPA2 | protein_coding | protein_coding | ENST00000269159 | 8 | 49853 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.00106 | 0.955 | 125730 | 0 | 18 | 125748 | 0.0000716 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 0.851 | 140 | 171 | 0.817 | 0.0000114 | 1827 |
| Missense in Polyphen | 52 | 75.585 | 0.68797 | 780 | ||
| Synonymous | 0.695 | 64 | 71.5 | 0.895 | 0.00000499 | 614 |
| Loss of Function | 1.77 | 7 | 14.2 | 0.492 | 8.38e-7 | 170 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000216 | 0.000216 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.000218 | 0.000217 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.0000705 | 0.0000703 |
| Middle Eastern | 0.000218 | 0.000217 |
| South Asian | 0.00 | 0.00 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Can use myo-inositol monophosphates, scylloinositol 1,4- diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2'- AMP as substrates. Has been implicated as the pharmacological target for lithium Li(+) action in brain. {ECO:0000269|PubMed:17068342}.;
- Pathway
- Inositol phosphate metabolism - Homo sapiens (human);Phosphatidylinositol signaling system - Homo sapiens (human);superpathway of D-<i>myo</i>-inositol (1,4,5)-trisphosphate metabolism;Inositol phosphate metabolism;D-<i>myo</i>-inositol (1,4,5)-trisphosphate degradation;Metabolism;<i>myo</i>-inositol <i>de novo</i> biosynthesis;Inositol phosphate metabolism;Synthesis of IP2, IP, and Ins in the cytosol
(Consensus)
Recessive Scores
- pRec
- 0.236
Intolerance Scores
- loftool
- 0.424
- rvis_EVS
- 0.33
- rvis_percentile_EVS
- 73.27
Haploinsufficiency Scores
- pHI
- 0.539
- hipred
- Y
- hipred_score
- 0.654
- ghis
- 0.417
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.898
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Impa2
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); renal/urinary system phenotype; normal phenotype;
Gene ontology
- Biological process
- inositol biosynthetic process;phosphate-containing compound metabolic process;signal transduction;inositol phosphate metabolic process;phosphatidylinositol phosphorylation;inositol phosphate dephosphorylation
- Cellular component
- cytoplasm;cytosol
- Molecular function
- protein binding;inositol monophosphate 1-phosphatase activity;protein homodimerization activity;metal ion binding;inositol monophosphate 3-phosphatase activity;inositol monophosphate 4-phosphatase activity